Huanjie Yang1, Jeffrey A Zonder, Q Ping Dou. 1. The Prevention Program, Barbara Ann Karmanos Cancer Institute, and the Department of Pathology, School of Medicine, Wayne State University, 540.1 HWCRC, 4100 John R. Road, Detroit, Michigan 48201, USA.
Abstract
BACKGROUND: Emerging evidence demonstrates that targeting the tumor proteasome is a promising strategy for cancer therapy. OBJECTIVE: This review summarizes recent results from cancer clinical trials using specific proteasome inhibitors or some natural compounds that have proteasome-inhibitory effects. METHODS: A literature search was carried out using PubMed. Results about the clinical application of specific proteasome inhibitors and natural products with proteasome-inhibitory activity for cancer prevention or therapy were reviewed. RESULTS/ CONCLUSION: Bortezomib, the reversible proteasome inhibitor that first entered clinical trials, has been studied extensively as a single agent and in combination with glucocorticoids, cytotoxic agents, immunomodulatory drugs and radiation as treatment for multiple myeloma and other hematological malignancies. The results in some cases have been impressive. There is less evidence of bortezomib's efficacy in solid tumors. Novel irreversible proteasome inhibitors, NPI-0052 and carfilzomib, have also been developed and clinical trials are underway. Natural products with proteasome-inhibitory effects, such as green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG), soy isoflavone genistein, and the spice turmeric compound curcumin, have been studied alone and in combination with traditional chemotherapy and radiotherapy against various cancers. There is also interest in developing these natural compounds as potential chemopreventive agents.
BACKGROUND: Emerging evidence demonstrates that targeting the tumor proteasome is a promising strategy for cancer therapy. OBJECTIVE: This review summarizes recent results from cancer clinical trials using specific proteasome inhibitors or some natural compounds that have proteasome-inhibitory effects. METHODS: A literature search was carried out using PubMed. Results about the clinical application of specific proteasome inhibitors and natural products with proteasome-inhibitory activity for cancer prevention or therapy were reviewed. RESULTS/ CONCLUSION:Bortezomib, the reversible proteasome inhibitor that first entered clinical trials, has been studied extensively as a single agent and in combination with glucocorticoids, cytotoxic agents, immunomodulatory drugs and radiation as treatment for multiple myeloma and other hematological malignancies. The results in some cases have been impressive. There is less evidence of bortezomib's efficacy in solid tumors. Novel irreversible proteasome inhibitors, NPI-0052 and carfilzomib, have also been developed and clinical trials are underway. Natural products with proteasome-inhibitory effects, such as green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG), soy isoflavone genistein, and the spice turmeric compound curcumin, have been studied alone and in combination with traditional chemotherapy and radiotherapy against various cancers. There is also interest in developing these natural compounds as potential chemopreventive agents.
Authors: Marjorie G Busby; A Robert Jeffcoat; LeAnne T Bloedon; Matthew A Koch; Tracy Black; Kelly J Dix; William D Heizer; Brian F Thomas; Judith M Hill; James A Crowell; Steven H Zeisel Journal: Am J Clin Nutr Date: 2002-01 Impact factor: 7.045
Authors: Aminah Jatoi; Neil Ellison; Patrick A Burch; Jeff A Sloan; Shaker R Dakhil; Paul Novotny; Winston Tan; Tom R Fitch; Kendrith M Rowland; Charles Y F Young; Patrick J Flynn Journal: Cancer Date: 2003-03-15 Impact factor: 6.860
Authors: Elena A Pop; Leslie M Fischer; April D Coan; Matt Gitzinger; Jun Nakamura; Steven H Zeisel Journal: Menopause Date: 2008 Jul-Aug Impact factor: 2.953
Authors: John D Hainsworth; Anthony A Meluch; David R Spigel; John Barton; Lisa Simons; Christina Meng; Bruce Gould; F Anthony Greco Journal: Clin Genitourin Cancer Date: 2007-03 Impact factor: 2.872
Authors: Michael Frezza; Sarmad Hindo; Di Chen; Andrew Davenport; Sara Schmitt; Dajena Tomco; Q Ping Dou Journal: Curr Pharm Des Date: 2010-06 Impact factor: 3.116
Authors: William R Schelman; Anne M Traynor; Kyle D Holen; Jill M Kolesar; Steven Attia; Tien Hoang; Jens Eickhoff; Zhisheng Jiang; Dona Alberti; Rebecca Marnocha; Joel M Reid; Matthew M Ames; Renee M McGovern; Igor Espinoza-Delgado; John J Wright; George Wilding; Howard H Bailey Journal: Invest New Drugs Date: 2013-10-10 Impact factor: 3.850
Authors: Huanjie Yang; Dong Kui Sun; Di Chen; Qiuzhi Cindy Cui; Yan Yan Gu; Tao Jiang; Wei Chen; Sheng Biao Wan; Q Ping Dou Journal: Cancer Lett Date: 2009-12-03 Impact factor: 8.679
Authors: Sara Molatore; Eva Kiermaier; Christian B Jung; Misu Lee; Elke Pulz; Heinz Höfler; Michael J Atkinson; Natalia S Pellegata Journal: Mol Cancer Date: 2010-05-21 Impact factor: 27.401